ArticleCardio-oncology (London, England)2026
No detectable early subclinical cardiotoxicity within 12 weeks of thoracic radiotherapy under predominantly low cardiac dose exposure: a prospective cohort study.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEarly radiation-induced cardiac injury in patients receiving thoracic radiotherapy (RT) remains insufficiently characterized. Global longitudinal strain (GLS) and circulating biomarkers such as high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) may detect subclinical myocardialdamage.
methodsThis prospective single-center cohort study enrolled 47 adults with thoracic malignancies treated with curative-intent RT. Cardiac assessments were performed at baseline, 1 week, and 12 weeks post-RT. GLS was measured by two-dimensional speckle-tracking echocardiography, and hs-cTnT and NT-proBNP were quantified using high-sensitivity immunoassays. Mean heart dose (MHD) was categorized as < 10 Gy or ≥ 10 Gy to explore dose-stratified differences within this predominantly low-dose exposure cohort. Temporal changes and dose-stratified differences were analyzed using non-parametric tests.
resultsGLS remained stable across timepoints (median - 18.06% at baseline, - 18.72% at week 1, and - 18.59% at week 12; p = 0.650). Similarly, hs-cTnT showed no significant variation (7.30, 7.50, and 6.60 ng/L, respectively; p = 0.842), and NT-proBNP demonstrated modest, non-significant increases (43.0, 48.5, and 55.5 pg/mL; p = 0.797). Stratification by MHD revealed no significant differences in GLS or biomarker levels at any timepoint. No dose-dependent associations were observed These findings were consistent across subgroups and in sensitivity analyses restricted to completers, in a cohort with a median MHD of 5.1 Gy.
conclusionsContemporary thoracic RT was not associated with detectable early subclinical cardiotoxicity within the first 12 weeks under predominantly low cardiac dose exposure. Early cardiac alterations may depend on higher radiation exposure or longer follow-up, supporting longitudinal surveillance strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.